Equitable Access to High-Cost Pharmaceuticals

Research output: Book/ReportBook

Abstract

Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.
LanguageEnglish
PublisherElsevier
Number of pages238
Edition1st
ISBN (Electronic)9780128119624
ISBN (Print)9780128119457
Publication statusPublished - 21 Feb 2018

Fingerprint

Costs and Cost Analysis
Orphan Drug Production
Pharmaceutical Preparations
Delivery of Health Care
Biomedical Technology Assessment
Precision Medicine
Policy Making
Public Policy
Health Policy
Research
Public Health
Economics
Research Personnel
Guidelines
Health
Neoplasms
Organisation for Economic Co-Operation and Development

Cite this

@book{3510f4fcc0e7472981cf39cc3e087de5,
title = "Equitable Access to High-Cost Pharmaceuticals",
abstract = "Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.",
editor = "Zaheer-Ud-Din Babar",
year = "2018",
month = "2",
day = "21",
language = "English",
isbn = "9780128119457",
publisher = "Elsevier",
edition = "1st",

}

Equitable Access to High-Cost Pharmaceuticals. / Babar, Zaheer-Ud-Din (Editor).

1st ed. Elsevier, 2018. 238 p.

Research output: Book/ReportBook

TY - BOOK

T1 - Equitable Access to High-Cost Pharmaceuticals

A2 - Babar, Zaheer-Ud-Din

PY - 2018/2/21

Y1 - 2018/2/21

N2 - Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.

AB - Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.

M3 - Book

SN - 9780128119457

BT - Equitable Access to High-Cost Pharmaceuticals

PB - Elsevier

ER -